Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644748 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1311519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Revealing AIEC Virulence Genes Behind the Mask of Antimicrobial Resistance.
Cell Mol Gastroenterol Hepatol
January 2025
Ruy V. Lourenço Center for Emerging and Re-Emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey; Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey. Electronic address:
Using toxidromes in the ICU.
Intensive Care Med
January 2025
Department of Emergency Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
ILCOR World Restart a Heart - Spreading global CPR awareness and empowering communities to save lives since 2018.
Resusc Plus
January 2025
Emergency Department, Calderdale & Huddersfield NHS Trust, Halifax, UK.
The International Liaison Committee on Resuscitation (ILCOR) World Restart a Heart (WRAH) Initiative is helping to save countless lives by promoting a culture of preparedness and encouraging widespread lay cardiopulmonary resuscitation (CPR) training. In total from 2018 to 2023 at least 12.6 million people were trained, and 570.
View Article and Find Full Text PDFHigher monomeric C-reactive protein levels are associated with premature coronary artery disease.
Front Immunol
January 2025
Laboratory of Cell Hemostasis, Chazov National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia.
Introduction: Chronic inflammation is a major risk factor for coronary artery disease (CAD). Currently, the inflammatory cardiovascular risk is assessed via C-reactive protein (CRP) levels measured using a high-sensitivity assay (hsCRP). Monomeric CRP (mCRP) is a locally produced form of CRP that has emerged as a potential biomarker of inflammation.
View Article and Find Full Text PDFCD56 CD16 cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.
Front Immunol
January 2025
Team Immunity and Cancer, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Paoli-Calmettes Institute, University of Aix-Marseille UM105, Marseille, France.
Introduction: Acute myeloid leukemia (AML) is a rare haematological cancer with poor 5-years overall survival (OS) and high relapse rate. Leukemic cells are sensitive to Natural Killer (NK) cell mediated killing. However, NK cells are highly impaired in AML, which promote AML immune escape from NK cell immune surveillance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!